Orphazyme AS (OZYMF)

[ALERTS100%to10000%GAIN]

is old news but not looking good Orphazyme A/S : Says Study of Amyotrophic Lateral Sclerosis Drug Fails to Meet Primary, Secondary Endpoints
05/07/2021 | 07:02am EDT
share with twitter
share with LinkedIn
share with facebook
(MT Newswires) -- Orphazyme A/S (ORPH) said Friday its phase 3 trial of arimoclomol to treat amyotrophic lateral sclerosis did not meet its primary or secondary endpoints.

The trial's primary endpoint was to evaluate the efficacy of chronic treatment with arimoclomol compared with placebo while the secondary endpoint included survival, functional improvement and slow vital capacity.

Topline data will be presented at the upcoming virtual European Network to Cure ALS meeting. No important safety signals were observed, the company said.

Shares fell nearly 30% in premarket trading

Price: 6.00, Change: -2.56, Percent Change: -29.91


© MT Newswires 2021